Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut  by Hixon, Julie A et al.
INTRODUCTION
CD40 is a 48-kd transmembrane protein that is a mem-
ber of the nerve growth factor/tumor necrosis factor (TNF)
receptor superfamily [1,2]. Members of the TNF receptor
superfamily are structurally homologous and function to
regulate cell proliferation, differentiation, and death using
shared signal transduction pathways [3]. Although originally
described as playing a role in humoral immune responses, it
is now known that CD40 plays a wider role in regulating
immune function by increasing both costimulatory mole-
cules and antigen presentation [4,5]. CD40 also contributes
to the inflammatory process by inducing the secretion of
inflammatory cytokines including interleukin (IL)-1, IL-6,
IL-12, and TNF-α [3].
CD40 is expressed on a variety of cell types including
monocytes, dendritic cells, endothelial cells, and carcinomas
[3]. The expression of CD40 on a variety of carcinomas
including those of the bladder, kidney, ovary, skin, and
breast and the role of CD40 in the promotion of immune
function makes CD40 an attractive target for immunother-
apy [6,7]. We and others have demonstrated both in vitro
and in vivo antitumor activity following CD40 stimulation
using both lymphomas [8-10] and solid-tissue carcinomas
[11,12]. Although CD40 stimulation occurs without any
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ABSTRACT
Interleukin (IL)-12 and antibodies against CD40 have demonstrated antitumor effects in a variety of in vivo model
systems. However, both agents can also mediate significant toxicities either when used following lethal TBI or when
administered in combination with other agents such as IL-2. In this study, we assessed the effects of anti-CD40
monoclonal antibody (MoAb) and IL-12 in lethally irradiated mice. Acute lethal toxicity was observed following the
administration of either 10 µg anti-CD40 MoAb (FGK45) or 0.5 µg of recombinant murine (rm)IL-12 that resulted
in 100% mortality of all mice within 4 to 6 days. Histological evaluation revealed destruction of the normal gut
architecture in both anti-CD40 MoAb– and rmIL-12–treated mice. Analysis of serum cytokine levels in the lethally
irradiated mice receiving anti-CD40 MoAb demonstrated a marked increase of interferon (IFN)-γ and IL-12 p40,
whereas mice receiving rmIL-12 demonstrated a marked increase of IFN-γ. Lethally irradiated IL-12 p40 knock-out
mice were resistant to anti-CD40–induced toxicity, suggesting that the lack of IL-12 p40 with no possibility of mak-
ing functional IL-12 p70 is key for this toxic reaction. Similarly, lethally irradiated IFN-γ knock-out mice were com-
pletely resistant to rmIL-12–induced toxicity, suggesting that IFN-γ is a major player in IL-12–mediated toxicity.
These results suggest that both anti-CD40 MoAb and rmIL-12 induce an acute fatal toxicity characterized by simi-
lar intestinal pathology and mediated in part by IFN-γ.
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adverse effects in the nonirradiated animal, we have previ-
ously reported an acute morbidity that affected the intestine
following CD40 stimulation in lethally irradiated mice [13].
The intestinal lesions and rate of morbidity observed in our
CD40-mediated toxicity models are very similar to those
observed following the administration of IL-12 with IL-2 in
nonirradiated mice.
IL-12 is an important proinflammatory cytokine that
stimulates the production of IFN-γ from natural killer (NK)
and T-cells and serves as a key initiator of cell-mediated
immune responses [14,15]. In addition, IL-12 has demon-
strated potent antiangiogenic and antitumor effects when
used alone [16,17] or in combination with IL-2 [18,19] that
are dependent on the production of IFN-γ [20]. Although
proinflammatory cytokines such as IL-12 and IL-2 play a
role in the immunotherapy of neoplastic disease, their use
can be complicated by the induction of lethal cytokine-
induced shock affecting the intestine and lungs [21]. Inter-
estingly, the rate of morbidity and the intestinal lesions in
both the IL-2/IL-12 and the anti-CD40 monoclonal anti-
body (MoAb) model systems are surprisingly similar. Both
demonstrated rapid morbidity, with all mice succumbing
within 4 to 6 days from elevated levels of proinﬂammatory
cytokines and the destruction of normal gut architecture.
Although the toxicity of the administration of IL-12 in com-
bination with IL-2 has been evaluated [21], the role of IL-12
administration following lethal total body irradiation (TBI)
in mice has been evaluated using only C57BL/6 mice [22].
Irradiation, either alone or in combination with chemo-
therapy, is commonly used in conventional cancer therapy
to reduce the tumor burden of the host. Changes in
cytokine proﬁles following irradiation therapy could result
in unexpected toxicity when cytokines are used to promote
efﬁcient host-antitumor immune responses. In the current
study, we evaluate the effects of IL-12 using mice that have
received TBI, and extend our ﬁndings concerning the acute
lethal toxicity observed following CD40 stimulation in
lethally irradiated mice to further deﬁne the mechanism of
CD40-mediated toxicity. We also present data that we have
published previously [13] as a comparison to the IL-12 data,
because the studies had been performed side by side.
MATERIALS AND METHODS
Mice
Female BALB/c and male and female BALB/c IFN-γ or
IL-12 p40 knock-out mice were obtained from the Animal
Production Area (National Cancer Institute [NCI]-Frederick,
Frederick, MD) and were not used until they were 8 weeks
of age. Animals were cared for humanely according to both
the US Public Health Policy on the Care and Use of Ani-
mals and the Guide for the Care and Use of Laboratory
Animals. NCI-Frederick facilities are accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International.
Antibodies and Recombinant Murine IL-12
Anti–mouse CD40 (FGK45, rat immunoglobulin G1
agonistic MoAb) was produced as ascites as described previ-
ously [8]. The antibody was at a concentration of 9.7 mg/mL,
kept frozen until use, and diluted in phosphate buffered saline
(PBS) for injections. Recombinant murine (rm)IL-12 was
purchased from Peprotech (Nutley, NJ). The cytokine was
reconstituted to a concentration of 1 mg/mL in PBS, stored
at –70°C until use, and diluted in PBS for injections.
Bone Marrow Transplantation
Recipient BALB/c, BALB/c IFN-γ, or BALB/c IL-12
p40 knock-out mice were exposed to a 137Cesium source at a
dose rate of 212 cGy/minute and received 750 cGy TBI.
Mice were then given 106 syngeneic bone marrow cells
(BMC) intravenously (IV). Additional studies were per-
formed to evaluate the role of irradiation in rmIL-12–
induced toxicity. For these studies, mice were exposed to
either 800 cGy, 700 cGy, or 600 cGy TBI, and given 106 syn-
geneic BMC IV. Immediately following irradiation and
transplantation in both model systems, the mice received
daily intraperitoneal (IP) injections of either murine ago-
nistic monoclonal CD40, clone FGK45 (10 µg), rmIL-12
(0.5 µg), or PBS control in 0.2 mL. Injections were begun
immediately following irradiation and transplantation and
continued daily for 4 to 5 days. All experiments were assayed
with 6 to 10 mice per group and were performed 2 to
6 times with a representative experiment being shown.
Histology
Selected organs including small intestine, colon, lungs,
and liver were ﬁxed in 10% formalin. Gut was collected in a
“swiss roll” for microscopic examination of maximal surface
area. Tissues were embedded in parafﬁn, sectioned at 5 µm,
and stained with hematoxylin and eosin. Slides were evalu-
ated microscopically by a veterinary pathologist without
reference to the various treatment groups. Grading was as
follows: 1, minimal; 2, mild; 3, moderate; 4, severe; M, miss-
ing; P, present; –, no significant lesion. The experiments
were performed 5 times with a representative being shown.
Serum Cytokine Determination
For determination of serum IFN-γ and IL-12 p40 levels,
blood was collected 48 hours after initial injection of either
agonistic anti-CD40 MoAb, rmIL-12, or PBS control. Samples
were assayed by enzyme-linked immunosorbent assay (ELISA)
using a Quantikine M mouse IFN-γ Immunoassay or IL-12
p40 Kits (R&D Systems, Minneapolis, MN). The assay was
performed according to instructions from the manufacturer.
RESULTS
Administration of Either Anti-CD40 MoAb or rmIL-12
Induces Rapid Toxicity in Lethally Irradiated Mice
We have previously demonstrated acute toxicity charac-
terized by the destruction of gut tissue following CD40
stimulation via MoAb in lethally irradiated mice [13]. Simi-
lar acute mortality and intestinal lesions have been demon-
strated in nonirradiated SCID mice treated with rmIL-12 in
combination with IL-2 [21]. Although morbidity was not
observed with IL-12 alone, mild intestinal lesions occurred
in the nonirradiated SCID mice, and these lesions were
exacerbated by the addition of IL-2. Therefore, we exam-
ined the administration of rmIL-12 using our lethal TBI
model in BALB/c (750 cGy), C57BL/6 (950 cGy), and
CB.17 SCID (350 cGy) mice and compared the results to
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the acute toxicity observed following administration of anti-
CD40 MoAb. To evaluate the effects of both rmIL-12 and
anti-CD40 MoAb following TBI, syngeneic BMC were
transferred into lethally irradiated (750 cGy) recipients,
and the mice were given either 10 µg anti-CD40 MoAb
(FGK45), 0.5 µg rmIL-12, or PBS control for 4 to 5 days,
beginning the day of irradiation and transplantation. All
BALB/c mice receiving either anti-CD40 MoAb or rmIL-12
died within 4 days after lethal TBI, whereas all control mice
survived (Figure 1). Similar results were observed in lethally
irradiated (950 cGy) C57BL/6 mice given anti-CD40 MoAb
and in lethally irradiated (350 cGy) CB17.SCID mice
treated with either anti-CD40 MoAb or rmIL-12 (data not
shown). It is of interest to note that although the lethally
irradiated (950 cGy) C57BL/6 mice succumbed follow-
ing anti-CD40 MoAb administration, they required a dose
of anti-CD40 MoAb that was 10 times greater than that
given to lethally irradiated (750 cGy) BALB/c mice to
demonstrate the same effect. In addition, lethally irradiated
(950 cGy) C57/BL6 mice were completely resistant to up to
1.0 µg of rmIL-12. Taken together, these data suggest that
there may be strain differences involved in anti-CD40
MoAb– and rmIL-12–mediated toxicity. Severe intestinal
lesions, which were similar in both treated groups (Table 1),
were the most likely cause of mortality in all affected strains
receiving either anti-CD40 or rmIL-12. The lungs and liv-
ers of the mice were found on histological evaluation to be
normal. The most extensive damage occurred in the villi of
the small intestine (Figure 2). Compared to the control
mice, treated mice had villi that were markedly blunted, and
many of the shortened villi were fused together. Villous
epithelium had variable cytoplasmic vacuolation and diffuse
karyomegaly. The lamina propria had an infiltrate of
mononuclear cells and neutrophils. Both control and treated
mice had mildly hyperplastic crypts. Lesions were also pres-
ent in the colons of mice receiving anti-CD40 MoAb or
rmIL-12 (Figure 3). The principal change was diffuse goblet
cell depletion, with foci of sloughed cells in the crypt
lumens. Some of the affected crypts were mildly hyperplas-
tic. These results demonstrate that administration of either
anti-CD40 MoAb or rmIL-12 following lethal TBI induces
rapid morbidity in several different strains of mice that is
characterized by the formation of signiﬁcant gut lesions that
are not observed in control mice, but the liver and lung
were unaffected.
Reduction of TBI Eliminates rmIL-12–Induced
Toxicity
We have previously demonstrated the elimination of
anti-CD40–induced toxicity using sublethally irradiated
mouse models [13]. To assess the role of TBI in rmIL-12–
induced toxicity, recipient BALB/c mice were given either
lethal or sublethal doses of irradiation, followed by the
transfer of syngeneic BMC and daily injections of rmIL-12
beginning at day 0 and continuing for 5 days. Administra-
tion of rmIL-12 following 800 cGy TBI resulted in rapid
mortality, with 100% of mice dying by day 6, whereas mice
irradiated with 700 cGy TBI demonstrated 60% mortality
Figure 1. Administration of either anti-CD40 MoAb (FGK45) or
rmIL-12 after lethal TBI induces acute lethal toxicity. BALB/c mice
were given 750 cGy TBI and syngeneic BMT followed by daily IP
injections of PBS, 10 µg anti-CD40 MoAb, or 0.5 µg of rmIL-12 for
5 days. All mice receiving either anti-CD40 MoAb or rmIL-12 demon-
strated significant (P < .0005) mortality by day 6, whereas 100% of
mice receiving control sera survived. Experiments were performed
5 times with similar results and used 6 to 10 mice per group.
Table 1. Effect of Administration of Anti-CD40 and rmIL-12 on Gut following Lethal Total Body Irradiation*
PBS Anti-CD40 Anti-CD40 rmIL-12 rmIL-12
Small Intestine
Villous blunting – 4MF 4MF 4MF 3MF
Villous fusion – 4MF 4MF 4MF 3MF
Karyomegaly – 2MF – 2MF 1MF
Colon
Goblet cell depletion – 3MF 3MF 3MF 4MF
Crypt cell hyperplasia – 1MF 1MF 2MF 2MF
Lymphoid depletion – – 4 – 4
Sloughed cells, crypt lumen – 3MF 3MF 2MF –
Lungs N N N N N
Liver
Inflammation – 2 – – –
*BALB/c mice were lethally irradiated, given a syngeneic BMT, and were given daily intraperitoneal injections of either PBS, 10 µg of anti-
CD40 MoAb, or 0.5 µg rmIL-12 for 4 days. Mice were killed for histological evaluation 24 hours after the last intraperitoneal injection. Lesions
were evaluated and scored as follows: 1, minimal; 2, mild; 3, moderate; 4, severe, MF, multifocal; –, no signiﬁcant lesion; N, normal. Experiments
were performed 5 times with similar results. Data represent individual mice.
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at day 6 (Figure 4). Similar to sublethally irradiated anti-
CD40–treated mice [13], 100% of mice receiving 600 cGy
TBI and rmIL-12 survived (Figure 4). Histological analysis
revealed a reduction in the severity of the lesions in the guts
of sublethally irradiated mice compared with that of mice
receiving lethal doses of irradiation in response to rmIL-12
administration (data not shown). Thus, similar to the dimin-
ished mortality and pathology observed following CD40
stimulation in sublethally irradiated mice, the severity of
rmIL-12–induced toxicity is also dependent on the intensity
of conditioning.
Figure 2. Anti-CD40 MoAb and rmIL-12 given after lethal TBI medi-
ate the destruction of small intestine. BALB/c mice received 750 cGy
TBI and syngeneic BMT followed by daily IP injections of 10 µg of
anti-CD40 MoAb, 0.5 µg rmIL-12, or control serum for 5 days. Mice
underwent complete necropsy 24 hours following the last IP injection.
A, BALB/c mice treated with control serum. Small intestine has normal-
length villi (V) and mildly hyperplastic crypts (C). B, BALB/c mice
treated with anti-CD40 MoAb. Villi (V) are extremely blunted; several
are fused (arrow). Cellular inﬁltrate in lamina propria (double arrow).
Mildly hyperplastic crypts (C). C, BALB/c mice treated with rmIL-12.
Blunted villi (V) similar to those observed with anti-CD40 MoAb treat-
ment; hyperplastic crypts (C). Experiments were performed 5 times with
1 to 3 mice undergoing histological evaluation in each experiment.
Hematoxylin and eosin, original magniﬁcation ×10.
Figure 3. Anti-CD40 MoAb and rmIL-12 given after lethal TBI
mediates goblet cell depletion in the crypts of the colon. BALB/c mice
received 750 cGy TBI and syngeneic BMT followed by daily IP injec-
tions of 10 µg of anti-CD40 MoAb, 0.5 µg rmIL-12, or PBS control
for 5 days. Mice underwent complete necropsy 24 hours following the
last IP injection. A, BALB/c mice treated with control serum. Many
goblet cells (G) are present in the crypts of the colon. B, BALB/c mice
treated with anti-CD40 MoAb. Goblet cells in crypts (C) are depleted
of mucus, which is present in crypt lumens (arrow) and streaming into
the bow lumen (L). C, BALB/c mice treated with rmIL-12. Goblet cell
depletion in crypts (C) similar to that observed with anti-CD40 MoAb
treatment; lumens with mucus and some sloughed cells (arrow). Mild
crypt hyperplasia. Experiments were performed 5 times with 1 to
3 mice undergoing histological evaluation in each experiment. Hema-
toxylin and eosin, original magniﬁcation ×20.
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Administration of Either rmIL-12 or Anti-CD40
MoAb Increases IFN-γ Levels in the Serum of 
Lethally Irradiated Mice
We have previously demonstrated an increase of IFN-γ in
the serum of lethally irradiated mice following CD40 stimula-
tion [13]. Therefore, the role of IFN-γ in rmIL-12–induced
toxicity was evaluated. Recipient BALB/c mice received
750 cGy TBI, followed by the transfer of syngeneic BMC.
The mice then received daily IP injections of 10 µg anti-
CD40 MoAb (FGK45), 0.5 µg rmIL-12, or PBS control.
Serum was collected from the mice following 4 injections of
anti-CD40 MoAb and rmIL-12, and IFN-γ levels were
assessed by ELISA. Results from these experiments demon-
strated a marked and signiﬁcant (P ≤ .05) increase in the level
of IFN-γ in the serum of lethally irradiated mice receiving
either anti-CD40 MoAb or rmIL-12 compared to that of
control mice (Table 2). These results suggest that IFN-γ may
play a role in both the anti-CD40 MoAb– and rmIL-
12–induced toxicities observed in lethally irradiated mice.
Absence of IFN-γ Eliminates rmIL-12–Induced
Toxicity
We have previously demonstrated a reduction in the
toxicity associated with anti-CD40 MoAb using IFN-γ
knock-out mice [13]. Given the high levels of IFN-γ in the
serum of lethally irradiated mice receiving rmIL-12, we
postulated that removal of IFN-γ would also reduce
rmIL-12–induced toxicity. To address the role of IFN-γ in
rmIL-12–induced toxicity, lethally irradiated BALB/c IFN-γ
knock-out recipients were given syngeneic BMC from IFN-γ
knock-out donors, and wild-type BALB/c control recipients
were given syngeneic BMC from wild-type BALB/c donors.
Mice then received either 0.5 µg rmIL-12 or PBS control
for 5 days. All of the wild-type mice receiving rmIL-12 suc-
cumbed by day 6, whereas 100% of the IFN-γ–deficient
mice receiving rmIL-12 survived (Figure 5). Histological
evaluation of IFN-γ–deficient mice receiving rmIL-12
demonstrated a dramatic lessening of the severity of intesti-
nal lesions including complete elimination of villi blunting
and fusion in the small intestine (Table 3; Figure 6B) and
marked reduction of the goblet cell depletion in the colon
(Figure 6D) compared to that in similarly treated wild-type
mice (Figure 2C and 3C). We have previously demonstrated
diminished lesions in the small intestine and colon of
IFN-γ–deficient mice receiving anti-CD40 MoAb [13].
Thus the mortality and gut lesions observed following
administration of rmIL-12 and anti-CD40 MoAb are due,
in part, to the production of IFN-γ.
Administration of Anti-CD40 MoAb to Lethally
Irradiated Mice Increases IL-12 Levels in the Serum
We have previously demonstrated the production of
IFN-γ following CD40 stimulation in lethally irradiated
mice [13]. IFN-γ knock-out mice, however, were afforded
only partial protection from anti-CD40–induced toxicity,
leading us to speculate that additional factors may be
involved in the mortality and destruction of normal gut
architecture observed following lethal TBI and CD40 stim-
ulation. Given the similarities in rate of mortality and
pathological changes observed in both rmIL-12– and anti-
CD40 MoAb–induced toxicities, we next evaluated the role
of IL-12 in anti-CD40–induced toxicity. Lethally irradiated
(750 cGy) BALB/c mice received syngeneic BMC followed
Figure 4. Decreased TBI eliminates rmIL-12–induced toxicity.
BALB/c mice were irradiated with either 800 cGy, 700 cGy, or 600 cGy
TBI, given a syngeneic BMT, and injected daily IP with 0.5 µg of
rmIL-12 or PBS control. All mice receiving 800 cGy and 60% of mice
receiving 700 cGy succumbed by day 6. All mice receiving 600 cGy
demonstrated signiﬁcant (P = .0003) survival compared to mice receiv-
ing 800 cGy. Experiments were performed 1 time with 10 mice per group.
Table 2. Serum IFN-γ Levels Increase after Lethal TBI and Administration
of Either Anti-CD40 MoAb or rmIL-12*
Conditions IFN-γ Level in Serum, pg/mL
Control WT <9.4 ± 0.07
Anti-CD40 WT 645.5 ± 6.4†
rmIL-12 WT 2712.5 ± 870†
*Lethally irradiated BALB/c wild-type (WT) mice were bled for
serum 48 hours after the initial injection of either 10 µg of anti-CD40
MoAb, 0.5 µg rmIL-12, or PBS control and assayed by enzyme-linked
immunosorbent assay. Data are the mean ± SD of 3 mice. Experiments
were performed twice with similar results.
†Signiﬁcantly different (P ≤ .05) from PBS-treated control.
Figure 5. Absence of IFN-γ improves survival in lethally irradiated
rmIL-12–treated mice. BALB/c WT or GKO mice were lethally irra-
diated and given a syngeneic BMT and daily IP injections for 5 days of
either 0.5 µg of rmIL-12 or PBS control. Mice deﬁcient in IFN-γ and
treated with rmIL-12 showed signiﬁcantly (P ≤ .0001) increased sur-
vival compared to similarly treated WT mice.
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by daily IP injections of either 10 µg anti-CD40 MoAb or
PBS control. Mice were bled for serum at day 2, and IL-12
p40 and p70 levels were assessed by ELISA. Results from
these experiments demonstrated a marked and significant
(P ≤ .001) increase in the level of IL-12 p40 in the serum of
lethally irradiated mice receiving anti-CD40 MoAb com-
pared to that of control mice (Table 2). A similar increase in
levels of IL-12 p70 was observed in lethally irradiated mice
receiving anti-CD40 MoAb (data not shown). These data
suggest that in addition to IFN-γ, IL-12 p40 plays a role in
the morbidity of lethally irradiated mice treated with anti-
CD40 MoAb.
Absence of IL-12 p40 Eliminates Anti-CD40–Induced
Toxicity
The high levels of serum IL-12 p40 in lethally irradiated
mice receiving anti-CD40 MoAb led to an investigation into
the role of IL-12 in anti-CD40–induced toxicity. Lethally
irradiated BALB/c p40 knock-out mice were given syn-
geneic BMC from BALB/c p40 knock-out donors, and wild-
type BALB/c control mice were given syngeneic BMC from
wild-type BALB/c donors. Mice were then treated daily for
4 days with either 10 µg anti-CD40 MoAb or PBS control.
Interestingly, all wild-type mice receiving anti-CD40 MoAb
following lethal TBI succumbed by day 4, whereas 100% of
Table 3. Absence of IFN-γ Diminishes rmIL-12–Induced Gut Damage*
WT WT WT WT WT WT WT GKO GKO GKO GKO GKO
Small Intestine Ctl Ctl Ctl IL-12 IL-12 IL-12 Ctl Ctl Ctl IL-12 IL-12 IL-12
Villous blunting 1MF – – 4MF 4MF 4MF – – – 1MF – –
Villous fusion – – – 3MF 4MF 4MF – 1MF 1MF – – –
Vacuolation, villi – – – 3MF 3MF 3MF – – – – – –
*BALB/c WT and IFN-γ knock-out (GKO) mice received lethal TBI and a syngeneic BMT, followed by daily intraperitoneal injections of
0.5 µg rmIL-12 or PBS control (Ctl) for 5 days. Mice were histologically evaluated 24 hours after the last intraperitoneal injection. Lesions were
evaluated and scored as follows: 1, minimal; 2, mild; 3, moderate; 4, severe; MF, multifocal; –, no signiﬁcant lesion. Experiments were performed
twice with similar results. Data represent individual mice.
Figure 6. Elimination of IFN-γ protects small intestine and colon from rmIL-12–mediated destruction. A and C, BALB/c GKO mice treated with
control serum. Small intestine (6A) has normal-length villi (V) and colon (6C) has crypts with normal populations of goblet cells (G). B and D,
BALB/c GKO mice treated with rmIL-12. Small intestine (6B) has normal-length villi (V), and there is a lessening of goblet cell (G) depletion in the
crypts of the colon (6D) compared to that of similarly treated WT mice (Figures 2 and 3). Experiments were performed 2 times with 1 to 3 mice
undergoing histological evaluation in each experiment. Hematoxylin and eosin, original magniﬁcation ×10.
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the IL-12 p40 knock-out mice survived (Figure 8). Histo-
logical evaluation of the mice revealed a marked reduction
of the villi blunting and fusion in the small intestine (Fig-
ure 9B) and complete elimination of goblet cell depletion in
the colon (Figure 9D) in the IL-12 p40 knock-out mice
compared to that of similarly treated wild-type control mice,
demonstrating destruction of normal gut architecture (Fig-
ure 2B and 3B). Thus IL-12 is a key mediator of anti-
CD40–induced mortality and intestinal destruction.
DISCUSSION
We have previously demonstrated a fatal cytokine-
induced disease affecting the intestine following lethal TBI
and CD40 stimulation. In this study, we have extended these
findings as well as demonstrated a rapid and fatal toxicity
affecting the intestine following lethal TBI and the adminis-
tration of rmIL-12 that occurs in several different strains of
mice. Interestingly, both the CD40- and IL-12–toxicity
model systems have similar kinetics with all treated mice
succumbing within 4 days, with the exception of C57BL/6
mice, which were completely resistant to up to 1.0 µg rmIL-12.
In addition, histological evaluation revealed identical lesions
in the guts of mice treated with either anti-CD40 MoAb or
rmIL-12. Similar to the results obtained with the anti-
CD40 MoAb toxicity system, decreasing the amount of con-
ditioning either reduced or eliminated rmIL-12–induced
toxicity. Not only does this ﬁnding demonstrate the impor-
tance of conditioning, it further illustrates the similarities
between the anti-CD40 MoAb– and rmIL-12–induced toxi-
cities. Given these similarities, we speculated that the same
mediator was responsible for the observed mortality and
pathology. Because we have previously demonstrated a role
for IFN-γ in anti-CD40–induced lethality, we evaluated for
the presence of IFN-γ using our IL-12 toxicity system.
Administration of rmIL-12 following lethal TBI
resulted in dramatic increases of serum IFN-γ levels com-
pared to those observed in control mice. IL-12 induces pro-
duction of IFN-γ from NK and T-cells, and a role for IFN-γ
in the antitumor and antiangiogenic effects of IL-12 has
been demonstrated [20]. IFN-γ is also involved in the activa-
tion of macrophages and primes them for the secretion of
other proinﬂammatory cytokines such as IL-1, IL-6, IL-12,
and IL-18 [23]. Although the production of proinflamma-
tory cytokines is important for early resistance to intracellu-
lar infections [15], these cytokines are also thought to be
involved in pathogenesis resulting in tissue injury to the gut
that is mediated by monocytes/macrophages and NK cells
[24]. Our data demonstrating the complete elimination of
morbidity and pathology following the administration of
rmIL-12 to IFN-γ knock-out mice further support the role
of IFN-γ as a mediator of tissue injury to the gut.
Although we have previously demonstrated a role for
IFN-γ in anti-CD40–induced toxicity [13], it is possible that
other proinﬂammatory cytokines such as endotoxin, IL-18,
IL-23, TNF, IL-2, or IL-12 may be involved in mediating the
observed pathology. This possible involvement of other
proinﬂammatory cytokines could explain why IFN-γ knock-
out mice were afforded only partial protection when used in
our anti-CD40 toxicity model. In nonirradiated mice, IL-12
administered in combination with either IL-2 [21] or IL-18
[24] has been shown to elicit rapid mortality within 4 to
6 days that is characterized by destruction of normal gut
architecture. Given the similarities in the rate of morbidity
and the intestinal lesions following administration of IL-12 to
those observed following administration of anti-CD40
MoAb, we evaluated for the presence of IL-12 in mice receiv-
ing anti-CD40 MoAb after lethal TBI toxicity. We observed
marked increases of IL-12 p40 in the serum of mice receiv-
ing anti-CD40 MoAb compared to that of control mice,
suggesting a role for IL-12 p40 in anti-CD40–mediated toxic-
ity. We next evaluated the role of IL-12 in the CD40 toxicity
model using IL-12 p40 knock-out mice. These data demon-
strated that an absence of IL-12 p40 completely eliminated
anti-CD40 MoAb–induced mortality and pathology, further
supporting the role of IL-12 as a mediator of toxicity follow-
ing lethal TBI and CD40 stimulation. These data, combined
with our previous data showing an increase of IFN-γ follow-
ing lethal TBI and CD40 stimulation, support the role of
Figure 7. Administration of anti-CD40 MoAb to lethally irradiated
mice increases IL-12 levels in serum. BALB/c mice received 750 cGy
TBI and a syngeneic BMT, followed by daily IP injections of 10 µg of
anti-CD40 MoAb or PBS control. Mice were bled for serum after
3 injections, and the serum was analyzed by ELISA. Mice given anti-
CD40 MoAb demonstrated signiﬁcantly elevated (P ≤ .001) serum IL-12
levels compared to similarly treated control mice. Data are presented as
a combination of 2 experiments with 2 to 3 mice per group.
Figure 8. Absence of IL-12 p40 improves survival in anti-CD40
MoAb–treated mice. BALB/c WT and IL-12 p40 knock-out (KO) mice
received 750 cGy TBI and a syngeneic BMT, followed by daily IP injec-
tions of control serum or 10 µg of anti-CD40 MoAb for 4 days. Mice
deﬁcient in IL-12 p40 receiving anti-CD40 MoAb demonstrated signiﬁ-
cantly (P = .0009) increased survival compared to similarly treated WT
mice. Experiments were performed twice using 7 to 10 mice.
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IFN-γ as an enhancer of IL-12 secretion from macrophages
[23] and suggest that these two cytokines may act together as
mediators of pathogenesis during an inﬂammatory process via
a positive feedback mechanism between IL-12–producing
macrophages and IFN-γ–producing T- and NK cells.
One possible scenario involving both IL-12 and IFN-γ as
mediators of toxicity following anti-CD40 administration
could occur via the enhancement of CD40 expression on
macrophages by IFN-γ [25], as well as the dependence of
macrophages on CD40-CD40L interactions [26,27] and IFN-γ
[23] for the production of IL-12. Given the role of CD40 in
the production of IL-12 from macrophages and the implication
of macrophages as mediators of IL-12 toxicity [21,24], it is pos-
sible that CD40 stimulation via an agonistic MoAb and the
resulting increase in the levels of IFN-γ [13] trigger the pro-
duction of large amounts of IL-12. Because IL-12 enhances the
secretion of IFN-γ from T- and NK cells [23], a mechanism of
uncontrolled cytokine production could be established in
which the positive feedback ampliﬁcation of IL-12 production
is enhanced by the production of IL-12–induced IFN-γ. It is
also possible that CD40 acts early in this pathway, with CD40
stimulation of macrophages inducing the secretion of multiple
proinﬂammatory cytokines including IL-1, IL-6, and TNF,
whereas the addition of rmIL-12 leads primarily to the produc-
tion of IFN-γ. This theory would explain why the absence of
IFN-γ affords complete protection from rmIL-12–mediated
toxicity, whereas anti-CD40–treated IFN-γ–deﬁcient mice are
only partially protected. It would be of interest to evaluate
whether IFN-γ is the sole mediator of IL-12–induced toxicity
in the CD40 model, and experiments using IL-12 p40 knock-
out and IFN-γ knock-out mice in the same experiment are cur-
rently being performed. In addition, it would be of interest to
neutralize IL-12 in IFN-γ knock-out mice.
Clearly conditioning plays a role in the observed toxicity
because unirradiated mice experience no toxic effects when
given up to 100 µg of anti-CD40 MoAb or 1.0 µg rmIL-12.
Intense myeloablative conditioning, either by irradiation or
chemotherapy, triggers an inflammatory cytokine cascade
resulting in the damage of intestinal mucosa and the secre-
tion of proinﬂammatory cytokines such as IL-1, IL-6, and
TNF-α. It is of interest to note that whereas lethally irradi-
ated BALB/c and CB.17/SCID mice were susceptible to
Figure 9. Elimination of IL-12 p40 protects small intestine and colon from anti-CD40 MoAb–mediated destruction. A and C, BALB/c IL-12 p40
knock-out mice treated with control serum. Small intestine (9A) has normal-length villi (V), and the colon (9C) has crypts with normal populations
of goblet cells (G). B and D, BALB/c IL-12 p40 knock-out mice treated with anti-CD40 MoAb. Small intestine (9B) has normal-length villi (V), and
the colon (9C) has crypts with normal populations of goblet cells (G), compared to similarly treated WT mice (Figure 2 and 3). Experiments were
performed 2 times with 1 to 3 mice undergoing histological evaluation in each experiment. Hematoxylin and eosin, original magniﬁcation ×10.
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both anti-CD40 MoAb– and rmIL-12–induced toxicity,
similarly irradiated C57BL/6 mice required 10 times the
amount of anti-CD40 MoAb to show the same toxic effects.
In addition, lethally irradiated C57BL/6 mice were com-
pletely resistant to up to 1.0 µg of rmIL-12. These data sug-
gest strain differences and support previous work by Sykes
et al. [22], who demonstrated no toxic effects following the
administration of rmIL-12 to lethally irradiated C57BL/6
mice that received a single fraction of lethal irradiation on
the day of bone marrow transplantation. In addition, Sykes
et al. [22] demonstrated that IFN-γ–deficient mice were
resistant to rmIL-12–induced toxicity, further supporting
our data obtained using IFN-γ knock-out mice.
The question of whether destruction of the gut by anti-
CD40 MoAb and rmIL-12 occurs directly or indirectly
remains unanswered. Gut lesions observed in our IL-12 and
CD40 toxicity models could be the result of direct targeting
of the normal gut tissue by IL-12 and an anti-CD40 MoAb,
and we are currently evaluating the direct effects of CD40
using CD40 knock-out mice. Conversely, toxicity could be
occurring via the activation of other effector cell popula-
tions, such as macrophages or NK cells, which could modu-
late tissue destruction via the production of inflammatory
cytokines. Although others have proposed a role for NK
cells in gut pathogenesis [24], we found that the depletion of
NK cells had no effect on either rmIL-12– or anti-CD40
MoAb–mediated toxicity (data not shown).
In conclusion, the data presented here demonstrate that
the administration of either anti-CD40 MoAb or rmIL-12
to lethally irradiated mice induces acute morbidity in
lethally irradiated mice, and the toxicity is mediated, at
least in part, by the production of IFN-γ. Anti-CD40
MoAb has demonstrated potent antitumor effects when
used in combination with IL-2 against murine solid-tissue
carcinomas (unpublished data). In addition, clinical trials
evaluating IL-12 in combination with IL-2 as an immuno-
therapy for cancer are currently in progress. Given the toxi-
city of high doses of inflammatory cytokines, it is hoped
that lower doses could be used to treat minimal residual
disease following the reduction of tumor burden in the host
with either chemotherapy or irradiation. However, synergy
between IL-2 and IL-12 in the induction of toxicity has
been demonstrated using lethally irradiated mice [28]. This
ﬁnding, as well as those of our studies, suggests that anti-
CD40 and rmIL-12 must be used prudently in patients
receiving myeloablative therapy.
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